Rio Tinto (ADR) vs Sana Biotechnology Inc — how do they compare? Rio Tinto (ADR) trades at $94.78 (market cap $150.89B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Rio Tinto (ADR) is far larger — about 180.3× Sana Biotechnology Inc's market cap, and Rio Tinto (ADR) pays a 4.98% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rio Tinto (ADR) for 10 Days and Sana Biotechnology Inc for 23 Days on average.
| RIO | SANA | |
|---|---|---|
Market Cap | $150.89B | $836.71M |
Volume | 1,492,444 | 4,507,444 |
Sector | Basic Materials | Health |
52-Week High | $112.04 | $5.92 |
52-Week Low | $65.44 | $2.68 |
Typical Hold Time | 10 Days | 23 Days |
Enterprise Value | $164.24B | $749.96M |
Dividend Yield | 4.98% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Rio Tinto is a global mining company that produces metals and minerals including iron ore, aluminium, copper, and lithium. Its operations supply materials used in construction, manufacturing, transportation, and energy systems.
Read more on RIO →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →